SNAP Trial

Current Staphylococcus aureus bacteraemia (SAB) treatment usually involves prolonged courses of exclusively intravenous (IV) beta lactam antibiotics
Prolonged IV antibiotic treatment is associated with an increased risk of adverse effects, inconvenience for patients, and high cost when compared to oral antibiotics
There is currently no evidence demonstrating superior clinical outcomes with IV administration compared to oral administration.
Current studies suggest that co-administration of oral beta-lactam antibiotics with probenecid (PCT therapy) significantly improves drug exposure in serum
This study aims to demonstrate the aforementioned effect of PCT in SAB infections, along with its potential as a safe and effective alternative to weeks of IV antibiotic therapy.

This substudy is being conducted in New Zealand.

Lead Investigators:

Dr. Max Bloomfield - Te Whatu Ora - Capital, Coast and Hutt Valley, Wellington Hospital (Maxim.Bloomfield@ccdhb.org.nz)

Dr. Genevieve Walls - Te Whatu Ora - Counties Manukau, Middlemore Hospital (Genevieve.Walls@middlemore.co.nz)

What will the substudy involve - more information

Blood samples will be collected during the intravenous and oral phases of each participant's treatment
A convenience sampling method will be used where possible (i.e at the same time of other necessary blood tests that are part of the hospital's standard of care)

Risks and benefits of taking part in this sub study

Risks:

Blood sample collection involves minimal volume and poses no significant risk to study participants
Antibiotic treatment involves some potential adverse events but are outlined as per SNAP core protocol.

SNAP Proposals

View All Proposals

C-SNAP

C-SNAP: Evaluating the prevalence of vitamin C deficiency and plasma vitamin C level decay in a prospective sample of patients with Staphylococcus aureus bacteraemia enrolled in the SNAP trial